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ABSTRACT 
Introduction: In the western hemisphere, 
age-related macular degeneration (AMD) is 
the leading cause of visual loss in the elderly. 
Currently approved therapies for AMD include 
argon laser, photodynamic therapy, and 
antivascular endothelial growth factor (VEGF) 
therapy. The index review discusses aflibercept 
(VEGF Trap-Eye) in the context of current 
anti-VEGF therapies for neovascular AMD and 
other retinal vascular diseases. It highlights 
important differences between VEGF Trap-Eye 
and currently used anti-VEGF therapies for 
neovascular AMD; and discusses the efficacy 
of these treatments utilizing information from 
landmark clinical trials.
Methods: A systematic search of literature was 
conducted on PubMed, Science Direct, and 
Scopus with no limitations of language or years 
of publication. 
Results: Preclinical studies have shown that 
VEGF Trap-Eye binds to VEGF-A with a higher 
affinity than other anti-VEGF molecules; and that 
it also binds to placental growth factor (PlGF). In 
clinical trials, VEGF Trap-Eye has been shown to 
be as effective in the treatment of neovascular 
AMD as other anti-VEGF therapies and possibly 
to have a longer duration of drug activity.  
Conclusion: VEGF Trap-Eye has enhanced 
the treatment options currently available for 
the management of neovascular AMD. The 
comparable efficacy of VEGF Trap-Eye (to other 
anti-VEGF agents) coupled with its longer 
dosing interval may decrease the number of 
annual office visits for patients with AMD and 
their caregivers. 
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referred to as retinal angiomatous proliferation 
[RAP]), based on their anatomic location [9]. 
METHODS OF LITERATURE REVIEW
Studies were identified through a comprehensive 
literature search of electronic databases (PubMed, 
Science Direct, and Scopus) with no limitations 
of language or year of publication. The following 
keywords and combinations of words were used 
in compiling the above search: ‘aflibercept,’ 
‘vascular endothelial growth factor’ (VEGF), 
‘VEGF,’ ‘antivascular endothelial growth factor‘ 
(anti-VEGF), ‘anti-VEGF,’ ‘vascular endothelial 
growth factor Trap-Eye,’ ‘VEGF Trap-Eye,’ ‘age-
related macular degeneration,’ ‘neovascular age-
related macular degeneration,’ ‘AMD,’ ‘diabetic 
macular edema’ (DME), ‘DME,’ ‘retinal vein 
occlusion’ (RVO), ‘RVO,’ ‘branch retinal vein 
occlusion’ (BRVO), ‘BRVO,’ ‘central retinal vein 
occlusion’ (CRVO), and ‘CRVO.’
CURRENTLY APPROVED THERAPIES 
FOR NEOVASCULAR AMD
Current established therapies for the treatment 
of neovascular AMD include argon laser 
therapy, photodynamic therapy (PDT), and 
anti-VEGF therapy.
Laser Therapy
Thermal laser photocoagulation has been approved 
for extrafoveal or juxtafoveal classic CNV based on 
results from the Macular Photocoagulation Study 
conducted in the1980s [10–13]. 
Photodynamic Therapy
In April 2000, the US Food and Drug 
Administration (FDA) approved verteporfin 
for treating patients with predominantly 
INTRODUCTION
Age-related macular degeneration (AMD) is the 
leading cause of visual loss and visual disability 
in patients aged ≥ 50 years in Europe and North 
America [1–4]. The Age-Related Eye Disease 
Study (AREDS) has categorized AMD into three 
stages: early, intermediate, and advanced. 
Advanced AMD is defined as having foveal 
geographic atrophy or presence of choroidal 
neovascularization (CNV). Geographic atrophy is 
characterized by atrophy of the retinal pigment 
epithelium and loss of the photoreceptor 
layers. Neovascular (wet) AMD is characterized 
by choroidal neovascularization. While non-
neovascular (dry) AMD accounts for 90% of 
cases of AMD, neovascular AMD is responsible 
for majority of cases of severe vision loss due 
to AMD [5].
Traditionally, CNV lesions of neovascular 
AMD are classified into classic or occult on 
fluorescein angiography (FA), which differ in 
clinical course and response to various treatment 
modalities [6]. Classic lesions demonstrate 
early hyperfluorescence and are usually well 
circumscribed. Occult lesions are poorly 
defined and show late hyperfluorescence. A 
predominantly classic lesion includes more 
than 50% classic CNV, a minimally classic lesion 
includes less than 50% classic CNV, and an 
occult lesion includes less than 1% classic CNV.
In recent years, a classification for CNV 
lesions based on multiple imaging modalities 
(FA, indocyanine green angiography, and 
spectral domain optical coherence tomography 
[OCT]) has been employed [7, 8]. Such 
classification categorizes CNV lesions as type 1 
(CNV beneath the retinal pigment epithelium 
[RPE]), type 2 (CNV that has penetrated the 
RPE/Bruch membrane complex and is present 
in the subretinal layer above the RPE), and 
type 3 (intraretinal neovascularization formerly 
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the treatment of neovascular AMD [18]. On 
November 18, 2011, the FDA approved VEGF 
Trap-Eye for the treatment of patients with 
neovascular AMD. The recommended dosage 
of VEGF Trap-Eye injection is 2 mg given every 
4 weeks for the first 12 weeks, followed by 2 mg 
every 8 weeks [19].
Surgery
The Submacular Surgery Trial (SST), a large, 
randomized clinical trial, has not established 
any significant benefit of surgery in patients 
with AMD [20, 21]. Surgical therapies, including 
submacular surgery and macular translocation, 
are currently recommended only in neovascular 
AMD cases where anti-VEGF therapy has not 
been shown to be effective [22]. 
classic subfoveal CNV secondary to AMD [14]. 
The approval was based on the results of the 
Treatment of Age-Related Macular Degeneration 
with Photodynamic Therapy (TAP) Study [15]. 
Results from the TAP and Verteporfin in 
Photodynamic Therapy (VIP) studies have also 
allowed the Centers for Medicare and Medicaid 
Services to cover PDT for occult and minimally 
classic lesions less than four disc areas in size [16].
Anti-VEGF Therapy
In December 2004, the FDA approved intravitreal 
(IVT) administration of 0.3 mg pegaptanib 
sodium every 6 weeks for the treatment of all 
forms of neovascular AMD [17]. Two years 
later, in June 2006, monthly IVT injections of 
ranibizumab (RBZ) 0.5 mg were approved for 
Table 1  Comparison among different VEGF antagonists
Aflibercept Ranibizumab Bevacizumab Pegaptanib
Molecular 
structure
Fusion protein: domains 
of VEGFR1 and 
VEGFR2 fused with 
IgG1 Fc [26]
Monoclonal IgG 








Binds to all forms of 
VEGF-A, VEGF-B, and 
PlGF [26, 27]
Binds to all forms of 
VEGF-A [31]
Binds to all forms of 
VEGF-A [30]




4.79 days  
(in rabbits) [29]
2.88–2.89 days for  
0.5 mg (in rabbits)  
[31, 34] 2.63 and  
3.9 days for 0.5 mg and  
2 mg  (in monkeys) [35]
4.32–6.61 days for  
1.25 mg (in rabbits) [32]
6.7 days for 1.25 mg  
(in humans) [30]
10 ± 4 days (in humans) 
[33, 36]
FDA approval Neovascular AMD [28] Neovascular AMD, 
macular edema 
secondary to retinal vein 
occlusion [18, 37]
Metastatic renal and 
colorectal cancers; 
glioblastoma;
non-small cell lung 
cancer [38]
Off-label use for AMD
Neovascular AMD [17]
AMD  age-related macular degeneration, Fab  fragment antigen binding, FDA  Food and Drug Administration,  
IgG1 Fc  immunoglobulin G1 Fragment, crystallizable, PlGF placental growth factor, R1  receptor 1, R2  receptor 2,  
RNA  ribonucleic acid, VEGF  vascular endothelial growth factor
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NOVEL PHARMACOLOGIC 
AGENTS AS TREATMENTS FOR 
NEOVASCULAR AMD
A variety of molecules are currently being studied 
for the treatment of neovascular AMD. These 
drugs target various mediators and receptors 
involved in the angiogenic pathway. They 
include tyrosine kinase inhibitors (valatinib, 
pazopanib, TG100801, TG101095, AG013958, 
AL39324), integrin inhibitors (JSM6427, 
volociximab), bioactive lipids (sonepcizumab), 
nicotine receptor antagonists (mecamylamine), 
vectors encoding for pigment epithelial derived 
factor (ADGVPEDF) and small interfering 
RNAs or siRNAs (PF-04523655, AGN211745, 
RTP801i-14) [23, 24].
The class of drugs that has shown to be 
most effective against angiogenesis is the VEGF 
antagonists [25]. The efficacy of these agents has 
been studied extensively in several phase 3 trials 
resulting in a paradigm shift in the management 
of neovascular AMD. A summary of the 
properties of anti-VEGFs currently employed 
in managing patients with neovascular AMD is 
presented in Table 1 [17, 18, 26–38]. 
THE VEFG PATHWAY
VEGF is  an important  mediator  of 
neovascularization. It also increases vessel 
permeability, and is about 50,000 times more 
potent than histamine in inducing vascular 
leakage [39]. The mammalian VEGF family 
includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
and PlGF (placental growth factor). VEGF-A165 is 
the most abundantly expressed and biologically 
active form in the human body [40].
VEGF-A acts on two transmembrane 
receptors located on the vascular endothelium, 
VEGFR1 and VEGFR2. Each receptor has 
seven immunoglobulin (Ig) domains in their 
extracellular regions. Binding of these domains 
with VEGF initiates the intrinsic tyrosine 
kinase activity of their cytodomains. Although 
VEGFR1 binds to VEGF with substantially 
higher affinity, most of the biologic effects of 
VEGF appear to be mediated by VEGFR2 [26]. 
Activation of these tyrosine kinases activates 
pathways that mediate endothelial migration 
and proliferation promoting angiogenesis; as 
well as effecting endothelial barrier functions 
causing leakage of water and macromolecules 
[41]. PlGF binds to VEGFR1 and has been shown 
to facilitate VEGF-A in promoting angiogenesis 
and vascular permeability, especially in 
pathological states [42–44].
VEGF-A165 and VEGF-A121 are most abundantly 
expressed in normal eye vasculature and high 
levels of these isoforms have been found in CNV 
tissues excised from AMD patients [43]. VEGF-A164 
and VEGF-A120 have also been implicated in the 
pathogenesis of CNV [45]. VEGF-A and PlGF have 
both been shown to promote angiogenesis and 
vascular leakage in the retina of animal and human 
models [43, 45–47].
VEGF TRAP-EYE (AFLIBERCEPT 
INJECTION)
Structure and Mechanism of Action
VEGF Trap-Eye (aflibercept injection) is 
a recombinant protein consisting of the 
fragment, crystallizable (Fc) portion of 
human immunoglobulin (Ig) G1 fused with 
human extracellular domains of VEGFR1 and 
VEGFR2 (Fig. 1).
It is created using “Traps” technology 
developed at Regeneron Pharmaceuticals, Inc., in 
which parts of two receptors are fused together 
along with an immunoglobulin constant region 
to create a soluble decoy receptor that has higher 
binding affinity to their cognate ligands than the 
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individual receptors themselves [48]. The VEGF 
Trap mRNA construct consists of sequences 
encoding the signal sequence of VEGFR1, fused 
with the Ig domain 2 of VEGFR1, which is fused 
to the Ig domain 3 from VEGFR2, which in turn 
is fused to the Fc domain of IgG1. There are no 
intervening sequences in this fusion construct. 
The VEGF Trap protein is then expressed as a 
secreted protein by Chinese hamster ovary (CHO) 
K1 cells with the signal sequence removed. The 
final protein molecule is a dimeric glycoprotein 
with a protein molecular weight of 97 kDa and 
contains ~15% glycosylation to give a total 
molecular weight of 115 kDa [49]. 
Final preparation of VEGF Trap-Eye involves 
ultra-purification of the VEGF Trap molecule by 
a combination of filtration and chromatographic 
techniques, which is then followed by titration 
of VEGF Trap into a buffer solution that is 
compatible with ocular tissues.
Pharmacodynamics
VEGF Trap has a significantly higher affinity 
for VEGF-A (Kd 0.5–1 pmol/L) [26, 27, 50] 
than other monoclonal anti-VEGF antibodies 
(Kd 0.1–10 nmol/L) [51, 52]. It has a higher 
affinity for the VEGF ligand than even natural 
VEGF receptors found on vessels and binds to 
VEGF in a 1 : 1 ratio. In addition to binding to 
all isoforms of VEGF-A, VEGF Trap also binds 
to VEFG-B and PlGF [28, 39]. When given IVT, 
VEGF Trap is rapidly distributed to the retina and 
is slowly absorbed into the systemic circulation 

















Fig. 1  Molecular construct of aflibercept, showing its possession of components from VEGF receptor 1 and VEGF receptor 2. 
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0.019 μg/mL (range 0 to 0.054 μg/mL) after a 
2.0 mg IVT injection occurring on the second day 
and declining rapidly to become undetectable in 
the circulation at approximately 7–14 days [28].
Pharmacokinetics
The half-life of human IVT VEGF Trap is unknown, 
but the half-life of IVT VEGF Trap given to animals 
is approximately 5 days [29]. Using a mathematical 
model based on known half-lives of bevacizumab 
(BVZ) in humans (6.7 days) and animals, the 
half-lives of VEGF Trap and RBZ in human eyes 
have been estimated to be 7.13 and 4.75 days, 
respectively [30, 53]. 
Free VEGF Trap is removed primarily from the 
circulation by binding to VEGF to form an inactive 
1:1 complex, and also by pinocytotic mediated 
proteolysis [52]. The inert complex is cleared 
by renal filtration [27]. The estimated clearance 
for free and bound VEGF Trap is 0.88 L/day and 
0.14 L/day respectively. The central volume of 
distribution of free VEGF Trap is 4.94 L and the 
half-maximal binding (Km) of free VEGF Trap 
binding to VEGF in the systemic circulation is 
2.91 μg/mL [54]. The half-life in systemic 
circulation increases with doses from 1.7 days at 
0.3 mg/kg to 5.1 days at 7.0 mg/kg [50].
Toxicity
Free VEGF Trap plasma concentrations following 
IVT administration of doses of up to 4 mg 
(approximately 0.057 mg/kg) are about two to 
three-times lower than free VEGF Trap plasma 
concentrations observed following intravenous 
(IV) administration of doses ≥ 1 mg/kg. Bound 
VEGF Trap plasma concentrations following 
IVT administration of doses of up to 2 mg/eye 
are approximately 20-fold lower than those 
observed following IV administration of doses 
of 0.3–4 mg/kg [28, 54, 55]. Systemic adverse 
events have been reported at IV administration of 
doses ≥ 1 mg/kg [50]. Therefore, systemic effects 
with IVT administration are unlikely; systemic 
adverse events have not been demonstrated to 
be clearly related to VEGF Trap-Eye in phase 1, 
2, or 3 clinical trials. No ophthalmic toxicity of 
the drug has been noted, but serious adverse 
events (SAEs) consistent with IVT injection 
administration have been reported [56–67]. 
Formulation
Aflibercept (VEGF Trap-Eye) is available as a 
preservative-free, sterile, aqueous solution in a 
single-use, glass vial designed to deliver 0.05 mL 
VEGF Trap (40 mg/mL in 10 mM sodium 
phosphate, 40 mM sodium chloride, 0.03% 
polysorbate 20, and 5% sucrose, pH 6.2) and 
needs to be stored at 2–8°C (36–46°F) [37].
Dosing
The recommended dosage of VEGF Trap-Eye for 
neovascular AMD, based on the approval by the 
FDA, is 2 mg given every 4 weeks for the first 
12 weeks, followed by 2 mg every 8 weeks. VEGF 
Trap-Eye may be dosed as frequently as 2 mg 
every 4 weeks [19, 68].
CLINICAL TRIALS WITH ANTI-VEGF 
PHARMACOLOGIC AGENTS AND 
IMPLICATIONS FOR NEOVASCULAR 
AMD THERAPY
Table 2 [69–81] summarizes important trials 
that have influenced current management of 
AMD with anti-VEGFs. The VEGF Inhibition 
S tudy  in  Ocula r  Neovascu la r i za t ion 
(VISION) trials established that pegaptanib 
(PEG) prevented vision loss over a period 
of 2 years in all forms of AMD, but no 
comparison was drawn with the use of PDT. 
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No significant gain in visual acuity (VA) was 
observed and the majority of patients continued 
to have vision loss with the use of pegaptanib in 
these trials [69, 70].
The Minimally Classic/Occult Trial of the 
Anti-VEGF Antibody Ranibizumab in the 
Treatment of Neovascular Age-Related Macular 
Degeneration (MARINA) and Anti-VEGF 
Antibody for the Treatment of Predominantly 
Classic Choroidal Neovascularization in Age-
Related Macular Degeneration (ANCHOR) trials 
established that RBZ not only prevented vision 
loss in all forms of AMD, but also improved 
vision in a subset of patients [71–73]. Patients 
in these trials were followed for 2 years and 
the results showed that the benefit of RBZ was 
maintained throughout the study period. In 
MARINA, there was a mean improvement of 
5.4 and 6.6 letters in the treatment arms (vs. a 
mean decline of 14.9 letters in the sham arm). 
The ANCHOR study specifically compared RBZ to 
PDT for the treatment of predominantly classic 
lesions and showed that patients receiving RBZ 
maintained vision superiorly compared with PDT. 
In addition, RBZ improved VA in a larger subset 
of patients than PDT. Over 2 years, there was a 
mean improvement of 8.1 and 10.9 letters in the 
treatment arms (vs. a mean decline of 9.8 letters 
in the PDT arm).
The RhuFab V2 Ocular Treatment Combining 
the Use of Visudyne to Evaluate Safety 
(FOCUS) study has shown that PDT given in 
conjunction with RBZ is superior to PDT given 
alone for predominantly classic lesions [74, 75]. 
Due to the heavy financial burden and 
inconvenience of monthly injections of RBZ for 
a prolonged period, the phase 3b, multicenter, 
randomized, double-masked, sham injection-
controlled study of the efficacy and safety of RBZ in 
subjects with subfoveal CNV with or without classic 
CNV secondary to AMD (PIER) and Prospective 
optical coherence tomography imaging of patients 
with intraocular ranibizumab (PrONTO) studies 
were conducted to explore and configure practical 
and economical regimens for RBZ administration. 
In the PIER study, monthly injections were given 
for 3 months followed by quarterly injections. 
However, it failed to show the same benefits that 
were seen when monthly injections were given 
in the MARINA and ANCHOR trials [76, 77]. On 
the other hand, the PrONTO study established 
that a regimen of 3 monthly injections followed 
by monthly follow-ups and PRN (pro re nata/ as 
needed) administration of RBZ is possible, with 
results comparable to the ANCHOR and MARINA 
trials. Patients in this study received an average of 
5.6 injections at the end of year 1 and 9.9 injections 
by the end of year 2. The PrONTO study, however, 
had a small sample size and was conducted at only 
one site [78, 79].
The Avastin (BVZ) for choroidal neovascular 
age-related macular degeneration (ABC) trial has 
shown that BVZ, being a similar molecule to RBZ, 
also prevents vision loss along with improving VA 
in a subset of patients [80]. Both RBZ and BVZ 
have been shown to have similar efficacy in the 
Comparison of Age-related Macular Degeneration 
Treatments Trials: Lucentis-Avastin Trial (CATT) 
trials, when given in a monthly regimen. RBZ 
given on a PRN basis also has a comparable 
efficacy to the monthly regimens. No conclusive 
comparison could be made for the prnBVZ group 
from the CATT trial [81].
Another strategy, the “treat and extend” 
regimen (TER) has been suggested in the clinical 
setting [82]. TER involves treating patients with 
an anti-VEGF agent monthly until there is no 
macular hemorrhage on examination or any 
intra- or sub-retinal fluid on OCT. The treating 
interval is prolonged by 2 weeks for every visit 
that there is no recurrence of exudation until a 
12 week interval is established. The patient is 
then given the option to discontinue treatment 
with a follow-up in 8 weeks or to continue 
Page 12 of 22 Biol Ther (2012)  2:3
12-weekly treatment. If at any time, there is 
evidence of recurrence of disease on examination, 
OCT or FA, or if VA is affected, the treatment 
interval is reduced by 2 weeks. Single-center 
retrospective studies using RBZ (92 eyes) and 
BVZ (74 eyes) have reported similar outcomes 
to those observed in MARINA and ANCHOR 
in eyes where TER was employed [83, 84]. The 
superiority of this regimen has been shown over 
PRN dosing in another retrospective review of 
90 eyes [85]. It is clear that the TER approach 
is more cost-effective than monthly injections; 
however, the level of evidence for the efficacy 
of this management approach is currently from 
retrospective trials. Nevertheless, such a strategy 
is currently being employed by the majority 
(60%) of retinal specialists in the US as recently 
reported in the 2011 Preferences and Trends (PAT) 
Survey conducted by the American Society of 
Retina Specialists.  
CLINICAL TRIALS WITH VEGF 
TRAP-EYE (AFLIBERCEPT INJECTION) 
IN NEOVASCULAR AMD
Preclinical studies have demonstrated the 
potential role of VEGF Trap in a number of 
vascular eye diseases including AMD [60, 86]. 
VEGF Trap-Eye was first studied in humans 
by Nguyen and colleagues at the Wilmer Eye 
Institute via intravenous administration of 
0.3 mg/kg, 1.0 mg/kg and 3.0 mg/kg against 
placebo in a phase 1 trial [61]. A dose-dependent 
decrease in foveal thickness (FTh) was noted, but 
due to two patients developing systemic toxicity 
in the 3.0 mg group (grade 4 hypertension and 
grade 2 proteinuria), the trial was halted [61].
The CLinical Evaluation of Anti-angiogenesis 
in the Retina Intravitreal Trial (CLEAR-IT-1) 
clinical trial was a two-part phase 1 study 
designed to investigate the safety of IVT VEGF 
Trap for AMD. The first part of the study 
was a dose escalation cohort of increasing 
concentrations; 0.05, 0.15, 0.5, 1, 2, and 4 mg 
IVT VEGF Trap in 21 patients. No systemic 
or ocular adverse events (AEs) were noted. A 
substantial reduction in FTh was observed, and 
95% of the patients remained stable or improved 
vision at 6 weeks [87]. The second part of the 
CLEAR-IT-1 study investigated the effect of a 
single intravitreal injection of 0.15 or 4 mg of 
VEGF Trap in 28 patients, with the primary 
endpoint at week 8. No SAE was reported in 
either group. The effects were substantially 
more prominent in the 4 mg group compared 
to the 0.15 group, as expected, illustrating the 
dose-response characteristics. FTh decreased by 
25% and 11% while VA improved by a mean of 
4.5 letters and 1.1 letters in the 4.0 mg and 
0.15 mg groups, respectively [88]. 
The CLEAR-IT phase 2 (CLEAR-IT-2) 
multicenter, double-masked clinical trial 
followed 159 patients, divided into five groups 
across 33 sites, for a year. Two groups were 
administered a monthly injection of 0.5 mg 
and 2.0 mg VEGF Trap-Eye while three groups 
were given 0.5, 2.0, and 4.0 mg VEGF Trap-Eye 
every 3 months. All patients received mandatory 
monthly or 3 monthly (based on the group 
designation) treatments for the first 3 months 
following the first treatment. After month 3, 
patients were evaluated each month and treated 
with the same dose of drug on a PRN basis. By 
the end of the mandatory treatment period, 
patients in groups 1 and 2 had received four 
treatments while patients in groups 3, 4, and 
5 had received two treatments. The 3-month 
results showed a mean reduction of 119 μm in 
central subfield thickness and a mean gain of 
5.7 letters across all groups. These improvements 
were significantly greater in the groups treated 
monthly compared to the groups treated 
3-monthly [56]. Improvements in anatomic and 
functional parameters were maintained through 
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month 13, with a mean reduction of 130 μm 
in central subfield thickness and a mean gain 
of 5.3 letters across all groups. The size of CNV 
as observed at month 12 on FA decreased in all 
groups. Overall, 92% of the study population 
lost fewer than 15 letters and 22% gained more 
than 15 letters. Patients received an average of 
two injections in the 9 months following the 
mandatory treatments [89].
The CLEAR-IT-2 trial showed that the 
monthly administration of VEGF Trap-Eye 
provided significantly greater improvement in 
both VA and foveal thickness (FTh) compared 
to every-3-month administration. The least 
number of injections (1.55) and the longest 
mean initial treatment-free interval (160 days) 
after mandatory treatments was observed in the 
2.0 mg monthly group. As highlighted before, 
the VEGF Trap-Eye molecule not only has a 
considerably favorable pharmacodynamic profile 
over other anti-VEGFs in its ability to bind to 
VEGF, it binds to PlGF as well. Such ability of 
persistent VEGF blockade led to the postulation 
of a possible longer treatment interval between 
injections of VEGF Trap compared to other 
anti-VEGFs. A mathematical model predicted 
VEGF Trap-Eye to maintain biological activity 
for 73–83 days compared to the activity of RBZ 
(30 days) [29]. On the basis of these results, 
phase 3 clinical trials VIEW 1 and VIEW 2 (The 
Vascular Endothelial Growth Factor [VEGF] 
Trap-Eye: Investigation of Efficacy and Safety in 
Wet Age-Related Macular Degeneration [AMD] 
Study) are being conducted.
VIEW 1 and VIEW 2 are two large, multicenter, 
randomized clinical trials that were designed 
to compare different treatment regimens of 
VEGF Trap-Eye to monthly RBZ. The studies 
were designed as noninferiority trials between 
VEGF Trap-Eye and RBZ. VIEW 1 has enrolled 
1,217 patients across sites in North America, 
while VIEW 2 has enrolled 1,240 patients across 
sites in Europe, Asia, and Latin America. There 
are four treatment groups: 0.5 mg RBZ monthly, 
0.5 mg VEGF Trap-Eye monthly, 2 mg VEGF Trap-
Eye monthly, and 2 mg VEGF Trap-Eye every 
2 months. All these groups received monthly 
injections for the first 3 months of the study [90].
At month 12, prevention of moderate vision 
loss (defined as losing less than 15 letters) was 
achieved in a similar percentage (94–95%) of 
patients in all four treatment arms across both 
trials. Patients in the 2.0 mg VEGF Trap-Eye 
group had a mean improvement of 10.9 letters 
in vision compared to 8.1 letters in the 0.5 mg 
monthly RBZ group. The other two groups were 
found to be noninferior to 0.5 mg RBZ monthly 
[62, 91]. The VIEW study design did not compare 
against a dosing regimen of RBZ given every 2 
months; thus, no comparison can be made to 
such a regimen.
In Year 2, all patients are being treated with 
the same dose no less frequently than every 
3 months but as frequently as every month if 
required in a “quarterly capped PRN” dosing 
schedule [64, 92]. According to a news release by 
Regeneron and Bayer on December 5, 2011, in 
an integrated analysis of the VIEW 1 and VIEW 
2 studies, the VA gain from baseline in the VEGF 
Trap-Eye 2.0 mg every other month group at week 
96 was 7.6 letters compared to 8.4 letters at week 
52, with an average of 11.2 injections over 2 years 
and 4.2 injections during the second year. The VA 
gain from baseline in the monthly RBZ group at 
week 96 was 7.9 letters compared to 8.7 letters at 
week 52, with an average of 16.5 injections over 
two years and 4.7 injections during the second 
year. The results of each of the VIEW 1 and VIEW 
2 studies were consistent with the integrated 
analysis [93]. 
The overall fewer average number of 
injections in the second year in the VEGF Trap-
Eye 2.0 mg every 2 months group compared to 
the RBZ group (4.2 vs. 4.7) was driven by the 
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fact that fewer patients needed more intense 
therapy in the VEGF Trap-Eye 2.0 mg every 
2 months. The proportion of patients who 
required frequent injections (six or more) during 
the second year was 15.9% in the VEGF Trap-
Eye 2.0 mg every 2 months group compared to 
26.5% in the RBZ group. In the 25% of patients 
who required the most intense therapy (the 
greatest number of injections), patients in the 
VEGF Trap-Eye 2.0 mg every 2 months group 
required an average of 1.4 fewer injections in 
the second year compared to the RBZ group 
(6.6 vs. 8.0). In the 25% of patients in each 
group who had the fewest number of injections 
in the second year, the average number of 
injections was similar (approximately 3 for both 
groups, corresponding to the protocol-mandated 
minimum number of injections). The statistical 
significance of these differences was not 
disclosed in this press release [93]. In addition, 
based on the currently available information, 
it is not clear if the difference between 4.2 and 
4.7 injections is clinically significant. Thus, it 
will be increasingly important to evaluate the 
efficacy and patterns of usage that are reported 
by clinicians as they begin to use aflibercept for 
neovascular AMD.
VEGF TRAP-EYE AND OTHER 
RETINAL VASCULAR DISEASES
In addition to neovascular AMD, VEGF Trap-Eye 
is also being studied as a potential therapy for 
DME and CRVO.
In an exploratory study of five patients, Do 
and colleagues at the Wilmer Eye Institute, 
demonstrated the safety and signals for bioactivity 
of VEGF Trap-Eye in eyes with DME. Each patient 
received one ITV injection of VEGF Trap-Eye.  Four 
patients showed improvement in FTh (median 
31% reduction from baseline) and VA (median 
improvement of three letters) at 6 weeks [59]. 
Following the pilot study, the DME And VEGF 
Trap-Eye: INvestigation of Clinical Impact 
(DAVINCI) phase 2 clinical trial compared 0.5 mg 
and 2.0 mg VEGF Trap-Eye monthly, 2 mg VEGF 
Trap-Eye bimonthly, and 2 mg VEGF Trap-Eye PRN 
to the current standard of care (laser therapy) in 
221 patients with DME [65, 66]. Six month results 
showed all four groups to be superior (mean 
letters gain of 8.5 to 11.4, mean FTh reduction 
of –127.3μm to –194.5 μm) to macular laser 
therapy (mean letters gain of 2.4, mean 
FTh –67.9 μm) [58]. Month 12 results have 
shown that the superiority of VEGF Trap-
Eye over laser has been maintained. Mean 
change in VA at week 52 was –1.3 letters for 
the laser group and 11, 13.1, 9.7, and 12 for the 
0.5 mg monthly, 2.0 mg monthly, 2.0 mg bimonthly, 
and 2.0 mg PRN groups, respectively [94]. 
Two large phase 3 trials, Study of Intravitreal 
Administration of VEGF Trap-Eye in Patients 
with Diabetic Macular Edema (VISTA-DME) and 
VEGF Trap-Eye in Vision Impairment Due to 
DME (VIVD-DME), are currently investigating 
two separate dosing regimens of VEGF Trap-Eye 
compared to focal laser photocoagulation for the 
treatment of DME [67].
COPERNICUS (Controlled Phase 3 Evaluation 
of Repeated intravitreal administration of VEGF 
Trap-Eye In Central retinal vein occlusion: 
Utility and Safety) and GALILEO (General 
Assessment Limiting Infiltration of Exudates in 
central retinal vein Occlusion with VEGF Trap-
Eye) are two phase 3 trials following 189 and 
172 patients with CRVO respectively. Patients are 
given monthly 2.0 mg VEGF Trap-Eye or sham 
injections for the first 6 months followed by 
PRN treatment for the next 6 months [63, 95]. 
At month 6, 56.1% and 60.2% of patients treated 
with VEGF Trap-Eye gained at least 15 letters 
from baseline compared to 12.3% and 22.1% of 
patients treated with sham, in the COPERNICUS 
and GALILEO studies, respectively [57, 94]. 
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The multicenter, randomized, controlled trial, 
CRUISE (a study of the efficacy and safety of 
RBZ injection in patients with macular edema 
secondary to CRVO), in which 392 CRVO 
patients received 6 monthly RBZ or sham 
injections followed by PRN treatment, has 
previously reported that 46.2% and 47.7% of 
patients in the RBZ groups and 16.9% of patients 
in the sham group gained at least 15 letters at 
month 6 [96]. At month 12, 47% and 50.8% 
in the RBZ groups, and 33.1% in the sham/
RBZ group had a gain of at least 15 letters [97]. 
Three hundred and four patients from CRUISE 
were followed in the HORIZON (An Open-
Label, Multicenter Extension Study to Evaluate 
the Safety and Tolerability of Ranibizumab in 
Subjects With Choroidal Neovascularization 
[CNV] Secondary to AMD or Macular Edema 
Secondary to RVO Who Have Completed a 
Genentech-Sponsored Ranibizumab Study) 
trial and seen at least every 3 months in a PRN 
regimen. At month 24 after CRUISE, 38.6% 
and 45.1% in the RBZ groups, and 38.3% in 
the sham/RBZ groups had a gain of at least 
15 letters [98]. Phase 3 studies of VEGF Trap-
Eye in branch retinal vein occlusion are being 
launched and will provide clinicians with 
additional and more complete data on the role 
of aflibercept in different types of RVO.
SAFETY PROFILE OF ANTI-VEGF 
THERAPY: WHAT HAVE WE LEARNED
Ocular SAEs after IVT injections in different 
clinical trials have been fortunately very low, with 
risks varying with underlying disease process, 
technique of administration and effect of the 
drug [99]. SAEs reported for anti-VEGF treatments 
specifically in multiple clinical trials have also 
been low with incidence rates per 100 injections 
as follows: endophthalmitis (0.04–0.11), retinal 
detachment (0.01–0.08), retinal tear (0.02–0.3), 
anterior chamber inflammation (0.25–1.06), 
cataract (0.05–0.64), increased intraocular pressure 
(IOP; 0.15–3.6) and intraocular hemorrhage 
(0.03–00.18) [58, 100–102]. 
Since VEGF is involved in a variety of 
physiologic processes such as blood pressure 
homeostasis [103], the question of AEs due to 
any systemic circulation of anti-VEGF given 
intravitreally arises. BVZ and aflibercept when 
given intravenously as chemotherapeutic agents 
have been known to cause hypertension and 
proteinuria, while BVZ has been identified as 
a risk for arterial thrombotic events (ATEs) and 
venous thrombotic events (VTEs) [104]. In the 
ANCHOR and MARINA trials, an increased but 
not significant rate of nonocular hemorrhages 
was noted in the treatment arms (9%) versus the 
sham arm (5.5%), raising some concern [105]. 
However, in other RBZ trials, including a phase 
4 study specifically designed to test the safety 
of RBZ injections (SAILOR-Safety Assessment 
of Intravitreal Lucentis for AMD), the rates of 
ATEs were similar to control groups [106]. In 
the CATT, the anti-VEGFs’ incidences of ATEs 
and VTEs were between 2–3% and 0–1.4%, 
respectively [81]. A large retrospective study 
of Medicare claims of 146,942 patients with 
neovascular AMD concluded that there was 
no increased risk of mortality, myocardial 
infarction, bleeding, or stroke in patients treated 
with BVZ and RBZ compared to photodynamic 
therapy or pegaptanib [107]. 
Thus far, data from the CLEAR-IT2 and VIEW 
studies have shown a similar safety profile 
as other anti-VEGFs. SAEs related to study 
injection, which included end ophthalmitis, 
traumatic cataract, and transient IOP elevation, 
were found to have an incidence of less than 
0.1% per injection, consistent with SAEs of IVT 
therapy. The most commonly reported AEs are 
conjunctival hemorrhage, eye pain, cataract, 
vitreous detachment, vitreous floaters, and 
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further decrease the number of annual office visits 
for AMD patients and their family members.
Although lesser frequency of treatments is 
expected with aflibercept (compared to BVZ or 
RBZ), the gain in VA has been similar among 
these three pharmacologic agents. Such findings 
may suggest that maximum visual gain has been 
achieved with aflibercept, BVZ, and RBZ as VEGF 
antagonists. Inhibiting other pathways involved 
in the pathogenesis of neovascular AMD and/or 
combination therapy may be required to achieve 
additional gain, supporting the rationale for 
additional research and clinical trials to search 
for other novel therapeutic approaches.  
CONCLUSION
VEGF antagonists have brought better therapeutic 
outcomes, compared to laser therapy, to patients 
with neovascular AMD, DME, and RVO. Starting 
with pegaptanib followed by RBZ, BVZ, and most 
recently aflibercept, each of these agents has 
confirmed again the important role of VEGF in the 
pathogenesis of many retinal vascular diseases. 
Aflibercept appears to provide longer duration of 
efficacy compared to RBZ in neovascular AMD, 
while being investigated further in DME and 
RVO. The safety profile of anti-VEGF therapy, in 
published studies thus far, has not shown to be 
very different among different agents. 
Studies are being done and research is being 
conducted to search for additional therapeutic 
approaches to enable patients with different 
retinal vascular diseases, including AMD, DME, 
and RVO, to achieve further visual gain while 
confronting no additional safety concerns. 
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Retina Specialists, in a letter to its members, 
and Regeneron, in a letter to the FDA, 
described a number of reported cases of ocular 
inflammation/noninfectious endophthalmitis 
following intravitreal injection of aflibercept for 
the treatment of neovascular AMD. It is unclear 
at this time if such inflammation will continue 
to be observed in the future and if it will affect 
the usage of VEGF Trap-Eye among clinicians. 
DISCUSSION
Anti-VEGF therapy has revolutionized the 
management of neovascular AMD, allowing 
nearly all patients to maintain their vision, 
while providing some patients with a gain of 
15 or more Early Treatment Diabetic Retinopathy 
Study (ETDRS)letters. Remarkable therapies, 
such as RBZ or BVZ, have enabled many elderly 
patients with neovascular AMD to preserve their 
vision and consequently their independence; a 
tremendous societal benefit.  
The approval of aflibercept offers another 
therapeutic option for patients with neovascular 
AMD. Aflibercept offers the potential of achieving 
the efficacy that patients and physicians have 
come to expect from current anti-VEGF agents, 
but with possibly less frequent injections and 
possibly no monitoring requirements. This may 
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